Is 10x Genomics, Inc. (TXG) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.2% / 30% | 19.7% / 30% | 3.1% / 30% | 3.12% / 5% | ✓ HALAL |
| DJIM | 3.2% / 33% | 19.7% / 33% | 3.1% / 33% | 3.12% / 5% | ✓ HALAL |
| MSCI | 8.1% / 33% | 50.3% / 33% | 7.9% / 33% | 3.12% / 5% | ✗ NOT HALAL |
| S&P | 3.2% / 33% | 19.7% / 33% | 3.1% / 33% | 3.12% / 5% | ✓ HALAL |
| FTSE | 8.1% / 33% | 50.3% / 33% | 7.9% / 50% | 3.12% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 69.1% | |
| Operating Margin | -9.4% | |
| Net Margin | -6.8% | |
| Return on Equity (ROE) | -5.8% | |
| Return on Assets (ROA) | -6.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $136M |
| Free Cash Flow | $130M |
| Total Debt | $84M |
| Debt-to-Equity | 10.6 |
| Current Ratio | 4.5 |
| Total Assets | $1.0B |
Price & Trading
| Last Close | $20.43 |
| 50-Day MA | $20.06 |
| 200-Day MA | $15.62 |
| Avg Volume | 2.6M |
| Beta | 2.2 |
|
52-Week Range
$6.78
| |
About 10x Genomics, Inc. (TXG)
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Purification Calculator
As a halal stock with 3.12% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is 10x Genomics, Inc. (TXG) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), 10x Genomics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is 10x Genomics, Inc.'s debt ratio?
10x Genomics, Inc.'s debt ratio is 3.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.1%.
Does 10x Genomics, Inc. require dividend purification?
Yes, 10x Genomics, Inc. has an impermissible income ratio of 3.12%, which means 3.12% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are 10x Genomics, Inc.'s key financial metrics?
10x Genomics, Inc. has a market capitalization of $2.5B, and revenue of $643M. The company maintains a gross margin of 69.1% and a net margin of -6.8%. Return on equity stands at -5.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.